Establish a pharmaceutical co-creation entity through joint investment to succeed Kyorin Pharmaceutical’s generic drug business. The co-creation entity will be capitalized by Daito, Meiji Seika Pharma and DBJ, and is planned to be established in December 2026. Preliminary transactions will be completed by March 2027, and the share transfer will be executed the same day. The impact is expected to be minor.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2269","jir_company_name":"Meiji Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/2269-20260930-01.pdf","jir_short_summary":"Establish a pharmaceutical co-creation entity through joint investment to succeed Kyorin Pharmaceutical's generic drug business. The co-creation entity will be capitalized by Daito, Meiji Seika Pharma and DBJ, and is planned to be established in December 2026. Preliminary transactions will be completed by March 2027, and the share transfer will be executed the same day. The impact is expected to be minor.","jir_summary":"### Key Points\nMeiji Holdings Co., Ltd.'s subsidiary Meiji Seika Pharma, together with Daito and DBJ, will jointly invest to establish a planned company, Pharmaceutical Co-Creation Organization Inc. (provisional), and succeed Kyorin Pharmaceutical's generic drug business. This matter involves conclusion of a joint venture agreement and a share transfer agreement. The co-creation entity plans to shift to a high-volume, low-variety production model utilizing the Takaoka and Inami plants. The establishment is planned for December 2026, the preparatory absorption-type split for this preliminary transaction is scheduled for March 31, 2027, and the effective date of succession will be April 1, 2027.\n\n### Schedule and Impact Going Forward\nThe contract signing date for this matter is September 30, 2026, and the share transfer agreement signing date is the same day; the establishment date of the co-creation entity is planned for December 2026. After the absorption-type split resulting from this preliminary transaction, the organization and succession of the target business, including the AG business, are expected to proceed. DBJ will invest using the Supply Chain Resilience Fund and is evaluated as contributing to strengthening regional economies and industrial competitiveness.","jir_financial_highlights":"Impact: The impact of this matter on the current fiscal year (fiscal year ending March 2027) consolidated results is expected to be minor, and there is no revision to the consolidated earnings forecast for the current fiscal year.","jir_category":"","jir_hashtags":"#MeijiHoldings, #PharmaceuticalCoCreationOrganization, #KyorinPharmaceutical, #GenericDrugs, #MandAAlliance","jir_key_figures":"Share transfer of the target company: Co-creation entity as purchaser, Kyorin Pharmaceutical as transferor (TBD, post-transfer ownership ratio 100.0%)\nCo-creation entity capital contribution ratio: Daito 49.1%, Meiji Seika Pharma 36.0%, DBJ 14.9%\nEstablishment date: December 2026 (planned)","jir_meta_title":"Meiji Holdings Co., Ltd. to Establish Joint Venture to Succeed Kyorin Pharmaceutical's Generic Drug Business | December 2026","jir_meta_description":"Meiji Holdings Co., Ltd., together with Meiji Seika Pharma, Daito and DBJ, will establish a co-creation entity to succeed Kyorin Pharmaceutical's generic drug business. Establishment is planned for December 2026, share transfer agreement signed on September 30, 2026, and business succession scheduled for April 2027. The impact on consolidated results is expected to be minor.","jir_og_title":"Meiji Holdings Co., Ltd. to Establish Joint Venture for Succession of Kyorin Pharmaceutical's Generic Drug Business","jir_og_description":"Meiji Holdings Co., Ltd. will establish a co-creation entity to succeed the generic drug business. Establishment is planned for December 2026, share transfer on September 30, and the impact is expected to be minor.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7598,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-124994","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n